Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b/3, Randomized, Double Blind, Dose Confirming Study of the Safety, Efficacy and Tolerability of Apricitabine Versus Lamivudine in Treatment-Experienced HIV-1 Infected Patients With the M184V/I Mutation in Reverse Transcriptase.

Trial Profile

A Phase 2b/3, Randomized, Double Blind, Dose Confirming Study of the Safety, Efficacy and Tolerability of Apricitabine Versus Lamivudine in Treatment-Experienced HIV-1 Infected Patients With the M184V/I Mutation in Reverse Transcriptase.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Apricitabine (Primary) ; Lamivudine
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 21 Apr 2012 Additional location (Germany) added as reported by European Clinical Trials Database record.
    • 24 Mar 2012 Additional locations (France. United Kingdom and Portugal) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top